| Active substance | Olaparib |
| Holder | AstraZeneca NV/SA |
| Status | Running |
| Indication | Lynparza® (olaparib) in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 05/11/2024 |